. 2008 Mar 18;8:3. doi: 10.1186/1475-2867-8-3

Table 1.

Dose-effect relationships of drug combinations in human androgen-independent prostate cancer cell line LNCaP C4-2B: Gefitinib (Ge), Lapatinib (La) and Cyclopamine (Cy).

Treatment	Parameters			CI value at			Range	Significance

	D_m	m	r	ED₅₀	ED₇₅	ED₉₀
Ge+Cy (12:1)	9.5	0.44	0.94	0.22	0.06	0.02	0.1–0.3	strong synergism
La+Cy (7:1)	5.8	0.44	0.94	0.14	0.06	0.03	0.1–0.3	strong synergism